The antitumor effects were associated with favourable pharmacokinetic properties, as evidenced by the amount of drug exposure in both plasma and tumour (Extended Data Fig. 10h,i), as well as a concordant inhibition of ERK phosphorylation and DUSP6 messenger RNA expression in tumour models (Extended Data Fig. 10j). This evidence concerns the gene DUSP6 and neoplasm.